Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package...
-
DALIAN, China, March 30, 2026 (GLOBE NEWSWIRE) -- CBAK Energy Technology, Inc. (NASDAQ: CBAT) (“CBAK Energy,” or the “Company”), a leading lithium-ion battery manufacturer and electric energy...
-
Ci-joint le rapport financier annuel 2025 Attachment Rapport Financier CRCAM 2025 ...
-
中國杭州, March 30, 2026 (GLOBE NEWSWIRE) --...
-
HANGZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- On March 27, CaoCao Mobility (stock code: 02643.HK) released its 2025 annual results announcement. During the reporting period, the Company...
-
FULL-YEAR 2025 RESULTS: SOLID GROWTH AND IMPROVED SECOND-HALF PROFITABILITY_____ Net sales: €242.6m (+ 11.4%)Net revenue (gross margin): €180.5m (+ 6.8%)EBITDA1: €23.7m (+0.8%), with a strong...
-
RÉSULTATS ANNUELS 2025 : CROISSANCE SOLIDE ET AMÉLIORATION DE LA RENTABILITÉ AU SECOND SEMESTRE_____ Chiffre d’affaires de 242,6 M€ (+11,4 %)Revenu net de 180,5 M€ (+6,8 %)EBITDA1 de 23,7 M€ (+0,8%),...
-
EBITDA Courant de 66,7 M€ (+9,1%) Résultat Opérationnel Courant 48 M€ (+6,8%) Progression du résultat Net de +8,8% à 41,1 M€
-
EBITDA of €66.7 million (+9.1%) Current operating income of €48.2 million (+6.8%) Net profit increased by 8.8% to €41.1 million
-
EUROCASTLE INVESTMENT LIMITED FOR IMMEDIATE RELEASEContact: Oak Fund Services (Guernsey) LimitedCompany AdministratorAttn: Nicole BarnesTel: +44 1481...